Wellington Management Group LLP Trims Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Wellington Management Group LLP decreased its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 6.7% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 454,649 shares of the company's stock after selling 32,486 shares during the period. Wellington Management Group LLP owned about 0.98% of Pacira BioSciences worth $6,842,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Innealta Capital LLC bought a new position in shares of Pacira BioSciences during the second quarter worth approximately $50,000. nVerses Capital LLC increased its stake in Pacira BioSciences by 800.0% during the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock worth $51,000 after acquiring an additional 1,600 shares during the period. CWM LLC raised its holdings in Pacira BioSciences by 713.6% in the 3rd quarter. CWM LLC now owns 6,517 shares of the company's stock valued at $98,000 after acquiring an additional 5,716 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Pacira BioSciences during the 2nd quarter valued at $113,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Pacira BioSciences by 62.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company's stock worth $134,000 after purchasing an additional 3,404 shares in the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Price Performance

PCRX stock traded down $0.04 during mid-day trading on Tuesday, reaching $19.83. 690,329 shares of the company traded hands, compared to its average volume of 850,727. The company has a fifty day moving average price of $17.35 and a 200-day moving average price of $18.89. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $35.95. The company has a market capitalization of $915.61 million, a P/E ratio of -9.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Analyst Ratings Changes

A number of research analysts recently issued reports on PCRX shares. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price objective on shares of Pacira BioSciences in a research note on Friday, November 8th. Royal Bank of Canada boosted their price target on Pacira BioSciences from $15.00 to $16.00 and gave the stock a "sector perform" rating in a report on Thursday, November 7th. HC Wainwright restated a "buy" rating and set a $39.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Jefferies Financial Group lifted their target price on Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. Finally, Barclays dropped their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Pacira BioSciences has a consensus rating of "Hold" and a consensus target price of $23.50.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.